On Wednesday, Pra Group Inc (NASDAQ:PRAA)’s shares inclined 0.68% to $54.81.
PRA Group (PRAA), a global leader in acquiring non-performing loans, recently declared that its partner, Portfolio Recovery Associates, LLC (“PRA”), has reached a settlement with the Consumer Financial Protection Bureau (“CFPB”), successfully negotiating a contract that will not materially impact operations and will allow the company to focus on future opportunities without distraction and avoid costly and time-consuming litigation.
Steve Fredrickson, chairman and chief executive officer of PRA Group, Inc., said, “It was time to end this drawn out process and eliminate the threat of litigation, so we can focus with renewed vigor on serving our customers and growing our business. Given the circumstances, we went the extra mile to achieve closure, despite our objection to the CFPB’s characterization of PRA’s business practices.
PRA Group, Inc., a financial and business service company, engages in the purchase, collection, and administration of portfolios of defaulted consumer receivables in North America and Europe. It is involved in the acquisition, collection, and processing of unpaid and normal-course accounts receivable owed to credit grantors, governments, retailers, and others.
iRobot Corporation (NASDAQ:IRBT)’s shares dropped -0.16% to $30.27.
iRobot Corp. (IRBT), the leader in delivering robotic technology-based solutions, recently declared the Roomba 980 vacuum cleaning robot – iRobot’s most capable and best cleaning robotic vacuum to date. Roomba 980 is the first Roomba to combine adaptive navigation with visual localization, cloud connected app control, and raised cleaning power on carpets, assisting people to keep cleaner floors throughout the entire home at the push of a button.
iRobot Corporation designs, builds, and markets robots for the consumer, defense and security, telemedicine, and mobile video partnershipmarkets worldwide. The company operates through two segments, Home Robots, and Defense and Security Robots. It provides consumer products, such as floor vacuuming, automatic floor mopping, floor scrubbing, and pool and gutter cleaning robots.
At the end of Wednesday’s trade, Chatham Lodging Trust (NYSE:CLDT)‘s shares dipped -0.13% to $22.64.
Chatham Lodging Trust (CLDT), a hotel real estate investment trust (REIT) focused on investing in upscale extended-stay hotels and premium branded select-service hotels, recently declared that its board of trustees has declared a monthly common share dividend of $0.10 for September 2015. The common dividend is payable October 30, 2015, to shareholders of record on September 30, 2015.
Chatham Lodging Trust is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It primarily invests in premium-branded upscale extended-stay and select-service hotels to create its portfolio. Chatham Lodging Trust was founded on October 26, 2009 and is based in Palm Beach, Florida.
Nevro Corp (NYSE:NVRO), ended its Wednesday’s trading session with 1.36% gain, and closed at $46.36.
Zosano Pharma Corporation (ZSAN), a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin, recently declared administration changes reflecting the evolution of the business from a R&D-oriented company to a commercially focused organization as it prepares for completion of the Phase 2 study for ZP-Glucagon in September and of the Phase 1 study for its ZP-Triptan product candidate by the end of 2015.
Pete Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, R&D will retire from the company, effective December 31, 2015. He will serve as a scientific advisor to Zosano for a period of one year after his retirement and will continue to guide the company’s R&D strategy.
Dr. Alataris was the Founder and held the roles of President, Chief Executive Officer and Chief Commercial Officer of Nevro Corp. (NVRO), a medical device company that has developed an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
Nevro Corp., a medical device company, develops and commercializes a neuromodulation platform for the treatment of chronic pain. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
